

Notice: This Material may be  
protected by copyright law.  
(Title 17 U.S. Code)

# The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids

Sean D. McAllister<sup>1</sup> · Liliana Soroceanu<sup>1</sup> · Pierre-Yves Desprez<sup>1</sup>

Received: 16 December 2014 / Accepted: 30 March 2015  
© Springer Science+Business Media New York 2015

**Abstract** As a therapeutic agent, most people are familiar with the palliative effects of the primary psychoactive constituent of *Cannabis sativa* (CS),  $\Delta^9$ -tetrahydrocannabinol (THC), a molecule active at both the cannabinoid 1 (CB<sub>1</sub>) and cannabinoid 2 (CB<sub>2</sub>) receptor subtypes. Through the activation primarily of CB<sub>1</sub> receptors in the central nervous system, THC can reduce nausea, emesis and pain in cancer patients undergoing chemotherapy. During the last decade, however, several studies have now shown that CB<sub>1</sub> and CB<sub>2</sub> receptor agonists can act as direct antitumor agents in a variety of aggressive cancers. In addition to THC, there are many other cannabinoids found in CS, and a majority produces little to no psychoactivity due to the inability to activate cannabinoid receptors. For example, the second most abundant cannabinoid in CS is the non-psychoactive cannabidiol (CBD). Using animal models, CBD has been shown to inhibit the progression of many types of cancer including glioblastoma (GBM), breast, lung, prostate and colon cancer. This review will center on mechanisms by which CBD, and other plant-derived cannabinoids inefficient at activating cannabinoid receptors, inhibit tumor cell viability, invasion, metastasis, angiogenesis, and the stem-like potential of cancer cells. We will also discuss the ability of non-psychoactive cannabinoids to induce autophagy and apoptotic-mediated cancer cell death, and enhance the activity of first-line agents commonly used in cancer treatment.

**Keywords** Cannabinoid · Cannabidiol · Cancer · Reactive oxygen species

## Endocannabinoids

The endocannabinoid system was discovered through research focusing on the primary psychoactive active component of *Cannabis sativa* (CS),  $\Delta^9$ -tetrahydrocannabinol (THC), and other synthetic cannabinoids (Pertwee 1997). The discovery that THC activated two G protein-coupled receptors (GPCRs) termed cannabinoid 1 (CB<sub>1</sub>) and cannabinoid 2 (CB<sub>2</sub>) prompted the search for the endogenous cannabinoid ligands (Mechoulam et al. 1995; Sugiura et al. 1995). To date multiple putative ligands termed endocannabinoids have been isolated, all consisting of arachidonic acid linked to a polar head group (Piomelli 2003). Within the body, endocannabinoids interact with cannabinoid receptors, and are synthesized, removed, and degraded through specific pathways that are still being defined (Pertwee 2006). The endocannabinoid system has been shown to modulate a wide array of physiological process including learning and memory, appetite, pain, and inflammation (Wilson and Nicoll 2002; Klein 2005).

## Plant-Derived Cannabinoids

While there are more than 60 cannabinoids in CS, those present in reasonable quantities include THC, cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), and cannabigerol (CBG) (McPartland and Russo 2001). Other major classes of compounds in marijuana include nitrogenous compounds, sugars, terpenoids, fatty acids, and flavonoids (Turner et al. 1980; Albanese et al. 1995; McPartland and

✉ Sean D. McAllister  
mcallis@cpmcri.org

<sup>1</sup> California Pacific Medical Center Research Institute, 475 Brannan Street, Suite 220, San Francisco, CA 94107, USA

Russo 2001). McPartland and Russo reported that the concentration range of THC in the dry weight of marijuana was 0.1–25 %, 0.1–2.9 % for CBD, 0–1.6 % for CBN, 0–0.65 % and 0.03–1.15 % for CBG. Of these, CBD has been studied the most extensively (Zuardi 2008). CBD has been reported to be devoid of psychoactive effects (Hollister and Gillespie 1975), is an anti-arthritic agent (Malfait et al. 2000), anxiolytic (Guimaraes et al. 1994), anti-convulsant (Turkanis and Karler 1975), a neuroprotective agent (Hampson et al. 1998), and inhibits cytokine production (Srivastava et al. 1998), to name a few characteristics. There are reports that it interferes with THC metabolism in vivo (Bornheim and Grillo 1998) and in vitro (Jaeger et al. 1996). CBD easily penetrates the brain (Alozie et al. 1980), but has low binding affinity for cannabinoids receptors and has been shown to act as cannabinoids receptor antagonist in certain models (Huffman et al. 1996; Pertwee 1997). CBD has been reported to have either no effect, enhance, or antagonize the effects of THC in laboratory animals (Brady and Balster 1980; Hiltunen et al. 1988) and in humans (Hollister and Gillespie 1975; Dalton et al. 1976; Hunt et al. 1981).

CBN is another marijuana constituent that has attracted considerable attention. It has weak THC-like effects (Perez-Reyes et al. 1973; Hiltunen et al. 1988; Hiltunen et al. 1989) and weak affinity for the cloned cannabinoid receptors (Huffman et al. 1996). After oral administration, CBN (40 mg/kg) had little influence on THC (20 mg/kg) pharmacokinetics in humans (Aguirell et al. 1981). CBD has been reported to attenuate CBN's effects (Jarbe and Hiltunen 1987) in one study and no effect in another (Hiltunen et al. 1988). As for the other constituents in marijuana, little is known about their pharmacological and toxicological properties. CBC is not pharmacologically active in monkeys (Edery et al. 1971), lacks anticonvulsant effects (Karler and Turkanis 1979), but was reported to produce CNS depression and slight analgesia in rodents (Davis and Hatoum 1983). CBG does not stimulate adenylyl cyclase (Howlett 1987), but does appear to have some weak analgesic properties (McPartland and Russo 2001).

## Overview of CB<sub>1</sub> and CB<sub>2</sub> Receptor Agonists as Antitumor Agents

In cancer cell lines, CB<sub>1</sub> and CB<sub>2</sub> agonists were first shown to modulate the activity of ERK, p38 MAPK and JNK1/2 (Galve-Roperh et al. 2000; McKallip et al. 2006; Sarfaraz et al. 2006; Ramer and Hinz 2008). However, there was a clear difference in the activity produced (sustained stimulation vs. inhibition) depending upon the agonist used and the cancer cell line studied. Initially, production of ceramide leading to sustained up-regulation of ERK activity by treatment with CB<sub>1</sub> and CB<sub>2</sub> agonists was shown to be an essential

component of receptor-mediated signal transduction leading to the inhibition of brain cancer cell growth both in culture and in vivo (Galve-Roperh et al. 2000; Velasco et al. 2004). In targeting primary tumor growth, this was later refined to include de novo-synthesis of ceramide leading to endoplasmic reticulum (ER) stress and induction of TRIB3 resulting in inhibition of pAkt/mTOR and the production of autophagy-mediated cell death (Carracedo et al. 2006a; Carracedo et al. 2006b; Salazar et al. 2009). Multiple reviews focusing on the antitumor activity of CB<sub>1</sub> and CB<sub>2</sub> receptor agonists have been published (Bifulco and Di Marzo 2002; Flygare and Sander 2008; Sarfaraz et al. 2008; Freimuth et al. 2010; Velasco et al. 2012).

## Non-Psychoactive Plant-Derived Cannabinoids as Inhibitors of Cancer

With the discovery that CB<sub>1</sub> and CB<sub>2</sub> agonists demonstrated antitumor activity, several groups began to investigate the potential antitumor activity of additional plant-derived cannabinoids (Table 1). These compounds either do not activate or are inefficient at activating CB<sub>1</sub> receptors, which means they produce little to no psychoactivity. Of these compounds, CBD has been the most extensively studied. As opposed to THC, the pathways responsible for antitumor activity of CBD, particularly in vivo, are just beginning to be defined. In culture, the most unifying theme for CBD-dependent inhibition of cancer cell aggressiveness is the production of reactive oxygen species (ROS) (Ligresti et al. 2006; Massi et al. 2006; McKallip et al. 2006; McAllister et al. 2011; Shrivastava et al. 2011; Massi et al. 2012; De Petrocellis et al. 2013). Recently, Singer et al. provided the first evidence in vivo that CBD-dependent generation of ROS is in part responsible for the antitumor activity of the cannabinoid. In tumors derived from glioma stem cells (GSCs), CBD inhibited disease progression, however, a portion of therapeutic resistance to the treatment in this subpopulation of tumor cells was the upregulation of anti-oxidant response genes (Singer et al. 2015).

Paradoxically, CBD is neuroprotective and multiple groups have shown selectivity for CBD inhibition of cancer cell growth in comparison to matched non-transformed cells (Massi et al. 2006; Shrivastava et al. 2011). Additionally, CBD has been shown to have antioxidant properties in neuronal cultures (Hampson et al. 1998). As discussed below, even with the lack of interaction with classical cannabinoid receptors, non-psychoactive cannabinoids appear to share similar mechanisms of action for targeting tumor progression.

## Inhibition of Cancer Cell Survival and Tumor Progression

Massi et al. first reported that CBD could inhibit human GBM viability in culture and that the effect was reversed in the

**Table 1** Overview of cannabinoids and their effects on aggressive cancers

Cancer	Compound	Phenotype	Major mechanism	Antagonism	Reference
Rat glioma	CBD	↓ cell viability	n.d.	n.d.	Jacobsson et al. 2000
Human glioblastoma	CBD	↓ cell viability ↑ apoptosis ↓ tumor growth	↑ ROS (implied by rescue experiments with TOC)	CB2: partial TOC: full Ceramide inhibitors: none PTX: none n.d.	Massi et al. 2004
Multiple human cancers	CBD-hydroxyquinone (HU-331)	↓ cell viability ↓ tumor growth (colon cancer) ↓ cell migration	n.d.	n.d.	Kogan et al. 2004
Human glioblastoma	CBD	↓ cell viability ↑ apoptosis	n.d.	CB1: none CB2: none PTX: none CPZ: none n.d.	Vaccani et al. 2005
Human glioblastoma	CBD	↓ cell viability ↑ apoptosis	↑ caspases ↑ cytochrome C ↑ ROS ↓ GSH	n.d.	Massi et al. 2006
Human leukemia	CBD	↓ cell viability ↑ apoptosis ↓ tumor growth and ↑ apoptosis in vivo	↓ procaspases and ↑ caspases ↓ PARP ↓ Bid ↑ cytochrome C ↑ ROS ↑ Nox4 and p22 <sup>phox</sup> ↓ P-p38 MAPK ↓ G1/S cell cycle arrest in some cells	CB1: none CB2: partial CPZ: none TOC: partial to full Apocynin: partial to full DPI: partial	McKallip et al. 2006
Multiple human cancers	Plant-derived and purified CBD CBD-A CBG CBC THC THC-A CBD	↓ cell viability ↑ apoptosis in some cells ↓ tumor growth ↓ metastasis	↓ P-glycoprotein substrate accumulation ↑ cytotoxic effects of vinblastine ↑ P-glycoprotein substrate accumulation ↑ cytotoxic effects of ABCG2 substrates e.g., topotecan ↓ cell viability	CB2: partial TRPV1: partial	Ligresti et al. 2006
Human leukemia	CBD	↑ P-glycoprotein substrate accumulation ↑ cytotoxic effects of vinblastine	↓ P-glycoprotein expression n.d.	n.d.	Holland et al. 2006
Human lines expressing P-glycoprotein	CBD, CBN, THC, THC-COOH	↑ P-glycoprotein substrate accumulation ↑ cytotoxic effects of ABCG2 substrates e.g., topotecan ↓ cell viability	n.d.	n.d.	Zhu et al. 2006
Multiple human cancer cell lines	CBD-hydroxyquinone (HU-331)	↓ cell viability	↓ topoisomerase II activity -not dependent on production of ROS	CB1: none CB2: none	Kogan et al. 2007
Mouse cell line over-expressing ABCG2 vs. wild-type	CBN, CBD, THC	↑ P-glycoprotein substrate accumulation ↓ ABCG2 ATPase activity ↑ cytotoxic effects of ABCG2 substrates e.g. topotecan ↓ tumor growth	n.d.	No CB1, CB2, or TRPV1 receptors detected by rtPCR	Holland et al. 2007
Human glioblastoma	CBD	↓ tumor growth	↓ 5-LOX ↑ leukotriene B4 ↓ AEA	n.d.	Massi et al. 2008

**Table 1** (continued)

Cancer	Compound	Phenotype	Major mechanism	Antagonism	Reference
Human cervical and lung cancer	CBD	↓ invasion ↓ metastasis	↑ FAAH activity ↓ TIMP1	CB <sub>1</sub> , CB <sub>2</sub> , VR <sub>1</sub> : full	Ramer et al. 2010a
Human lung cancer	CBD	↓ invasion ↓ tumor growth ↓ cell viability	↓ PAI	CB <sub>1</sub> , CB <sub>2</sub> , VR <sub>1</sub> : partial	Ramer et al. 2010b
Rat oligodendrocytes	CBD		↑ IC calcium ↑ ROS	CB <sub>1</sub> : none CB <sub>2</sub> : none	Mato et al. 2010
Human glioblastoma	CBD+THC	↓ cell viability ↓ invasion ↑ apoptosis	↓ Id1 ↑ caspase 3, 7, 9 ↑ PARP	A <sub>2A</sub> PPAR $\gamma$ : none THC+CB <sub>2</sub> -CB <sub>2</sub> :partial CBD- CB <sub>2</sub> : none	Marcu et al. 2010
Human and mouse breast cancer	CBD	↓ invasion ↓ metastasis	↑ ROS ↑ ROS ↓ Id1 ↑ G1/S transition ↑ pERK	TOC: partial ERK: partial	McAllister et al. 2010
Human glioblastoma	Plant-derived and purified CBD THC CBD+THC TMZ TMZ+CBD+THC	↓ cell viability ↓ tumor growth •CBD enhanced the antitumor activity of THC •THC or THC+CBD enhanced the antitumor activity of TMZ	↑ autophagy ↑ caspase 3 ↑ tunnel	CBD CB <sub>1</sub> : none CB <sub>2</sub> : none siATG1:none CBD $\pm$ THC CB <sub>1</sub> : partial CB <sub>2</sub> : partial siATG1:partial ISP: partial 3-MA: partial QVDOPH: full TOC: partial NAC: partial	Torres et al. 2011
Human breast cancer	CBD	↓ cell viability ↑ apoptosis	↑ ROS ↑ autophagy ↓ pAKT ↑ PARP ↓ mTOR ↓ 4EBP1 ↑ caspases ↑ t-Bid ↑ Bax * (see paper for additional pathways) ↓ MMP2, 9 ↓ uPA ↓ Endothelin-1 ↓ PGDF-AA ↓ CXCL16 ↓ PAI-1	Blocked by TOC and caspase inhibitor. Not blocked by CB <sub>1</sub> , CB <sub>2</sub> , A <sub>2A</sub> or PPAR $\gamma$ receptor antagonists.	Shrivastava et al. 2011
Human endothelial cells	CBD	↓ migration ↓ angiogenesis		n.d.	Solinas et al. 2012

**Table 1** (continued)

Cancer	Compound	Phenotype	Major mechanism	Antagonism	Reference
Human prostate cancer	CBD + several additional plant-derived and purified cannabinoids	<p>↓ cell viability</p> <p>↓ tumor growth</p> <p>•CBD enhanced or inhibited the antitumor activity of first-line agents depending on the cell line used</p>	<p>↓ IL-8</p> <p>↑ calcium</p> <p>↑ ROS</p> <p>↑ caspases</p> <p>↑ p53</p> <p>↑ tunel</p> <p>↓ G1/S transition</p> <p>↑ p21</p> <p>↑ PUMA</p> <p>↑ CHOP</p> <p>↑ COX-2</p> <p>↑ PPAR<math>\gamma</math></p> <p>↑ PGE2</p> <p>↑ PGD2</p> <p>↑ 15d-PGJ2</p> <p>↓ Id1</p> <p>↓ Sox2</p> <p>↓ pAKT</p> <p>↓ mTOR</p> <p>↓ pERK</p> <p>↓ Beta-catenin</p> <p>↓ PLCG1</p>	TRPM8; partial	De Petrocellis et al. 2013
Human lung cancer	CBD	<p>↓ cell viability</p> <p>↓ tumor growth</p>	<p>↑ COX-2</p> <p>↑ PPAR<math>\gamma</math></p> <p>↑ PGE2</p>	COX-2; full PPAR $\gamma$ ; full	Ramer et al. 2013
Human glioblastoma	CBD	<p>↓ invasion</p> <p>↓ neurosphere formation</p> <p>↓ tumor growth</p>	<p>↓ Id1</p> <p>↓ Sox2</p> <p>↓ pAKT</p> <p>↓ mTOR</p> <p>↓ pERK</p> <p>↓ Beta-catenin</p> <p>↓ PLCG1</p>	n.d.	Soroceanu et al. 2013
Human breast cancer	CBD and additional cannabinoids	CBD and THC did not interfere with the effectiveness of radiation		n.d.	Emery et al. 2014
Human and mouse breast cancer	CBD	<p>↓ cell viability</p> <p>↑ apoptosis</p> <p>↓ advanced stage metastasis</p> <p>↑ survival</p>	<p>↑ ROS</p> <p>↓ Id1</p> <p>↑ autophagy</p>	CB $_1$ : none CB $_2$ : none TOC: partial to full	Murase et al. 2014
Human and rat glioblastoma	Plant-derived and purified CBD, THC, CBD+THC	<p>↓ cell viability</p> <p>↓ tumor growth</p> <p>↑ apoptosis</p> <p>↓ angiogenesis</p> <p>•CBD+THC enhanced the effects of radiation</p>	<p>↑ pEPK</p> <p>↑ <math>\gamma</math>-H2AX</p> <p>↓ pAKT</p> <p>↑ autophagy</p> <p>↑ caspase 3</p>	n.d.	Scott et al. 2014
Human glioblastoma	CBD	<p>↓ cell viability</p> <p>↓ tumor growth</p> <p>↓ invasion</p> <p>↓ GSC self-renewal</p> <p>↑ ROS</p>	<p>↓ Id1</p> <p>↓ pSTAT3</p> <p>↓ p-p38MAPK</p> <p>↓ pAKT</p> <p>↓ Olig2</p> <p>↓ Sox2</p> <p>↑ CD44</p> <p>↑ NRF2</p> <p>↑ SLC7A11</p> <p>↓ NF<math>\kappa</math>B</p> <p>↓ pEGFR</p> <p>↓ pAKT</p>	n.d.	Singer et al. 2015
Human breast cancer	CBD	<p>↓ cell proliferation</p> <p>↓ colony formation</p> <p>↓ migration</p>	<p>↑ SLC7A11</p> <p>↓ NF<math>\kappa</math>B</p> <p>↓ pEGFR</p> <p>↓ pAKT</p>	n.d.	Elbaz et al. 2015

**Table 1** (continued)

Cancer	Compound	Phenotype	Major mechanism	Antagonism	Reference
Human melanoma	CBD+THC	<ul style="list-style-type: none"> <li>↓ invasion</li> <li>↓ primary tumor growth</li> <li>↓ metastasis</li> <li>↓ angiogenesis</li> <li>↓ macrophage recruitment to tumor</li> </ul> <ul style="list-style-type: none"> <li>↓ cell viability</li> <li>↓ tumor growth</li> </ul>	<ul style="list-style-type: none"> <li>↓pERK</li> <li>↓MMP2</li> <li>↓MMP9</li> <li>↓GM-CSF</li> <li>↓CCL3</li> <li>↓CXCL2</li> <li>↓arginase-1</li> <li>↓F4/80</li> <li>↓CD11b</li> <li>↑ autophagy</li> <li>↑ apoptosis</li> </ul>	n.d.	Armstrong et al. 2015

↓, down-regulated; ↑, up-regulated; *n.d.*, not determined

presence of ROS scavenger  $\alpha$ -tocopherol/vitamin E (Massi et al. 2004). In this study, CBD was also shown to inhibit tumor progression in a model where the GBM cells were implanted subcutaneously in xenograft mouse model. An early report by Jacobsson et al. demonstrated CBD could inhibit the viability of a rat glioma (C6) in culture, but no mechanism of action was reported (Jacobsson et al. 2000). Of note, this group demonstrated that the ability of plant-derived cannabinoids to inhibit cancer cell viability was enhanced under culturing conditions where the cells were serum-starved. This phenomenon appears to be primarily the result of the plant-derived cannabinoids binding to high molecular weight serum proteins (De Petrocellis et al. 2013).

Massi et al. went on to demonstrate that CBD-dependent production of ROS was accompanied by reduction in glutathione (GSH) and GSH-related enzymes (Massi et al. 2006). GSH is an important antioxidant that prevents damage to cellular components by ROS. The source of CBD-dependent stress in part originated in the mitochondria and led to activation of multiple caspases involved in intrinsic and extrinsic pathways of apoptosis. Further studies analyzing CBD-treated GBM tumor tissue revealed that inhibition of lipoxygenase (LOX) signaling played a role in CBD antitumor activity. In addition, the indirect modulation of the endocannabinoid system by CBD may have attributed to the observed antitumor activity. It should be noted that a CBD-hydroxyguinone (HU-311) was shown to inhibit prostate cancer cell viability and tumor progression in vivo (Kogan et al. 2004). It was later demonstrated that HU-311 inhibited topoisomerase II (Kogan et al. 2007) and HU-311 did not increase the production of ROS. A detail study of CBD-induced apoptosis was performed in human leukemia cells (McKallip et al. 2006). The investigators demonstrated a CBD-dependent increase in ROS production as well as an increase in the expression of the NAD(P)H oxidases Nox4 and p22<sup>phox</sup>. CBD treatment perturbed the function of the mitochondria as suggested by loss of mitochondrial membrane potential and release of cytochrome c. The cumulative cellular stress led to activation of multiple intrinsic and extrinsic caspases. Importantly, CBD treatment inhibited tumor progression and induced apoptosis in vivo.

### Interaction of CBD With Specific Receptors in Models of Cancer

A majority of investigations demonstrate that the ability of non-psychoactive cannabinoids (primarily CBD) to inhibit cancer cell viability/proliferation is not linked to direct interactions with CB<sub>1</sub> and CB<sub>2</sub> receptors, transient receptor potential cation channel subfamily V member 1 (TRPV1), adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>) or the peroxisome proliferator-activated receptor gamma (PPR $\gamma$ ) (Table 1). In certain cancer cell lines, the ability of CBD to inhibit cancer cell viability/

proliferation has been reversed in the presence of antagonists for CB<sub>2</sub>, TRPV1, TRPM8, COX-2, and PPR $\gamma$  (Table 1). Lung cancer cell lines appear to be particularly responsive to reversal of the anti-invasive effects of CBD in culture with antagonists to CB<sub>1</sub>, CB<sub>2</sub>, and TRPV1 (Ramer et al. 2010a; Ramer et al. 2010b). Currently, only two studies have investigated receptor dependence of CBD-dependent antitumor activity *in vivo*. In a model where tumors were derived from subcutaneous implanted human lung cancer cells, full reversal of CBD-dependent antitumor activity was observed in the presence of a PPR $\gamma$  antagonist (Ramer et al. 2013). It was recently demonstrated that the anti-metastatic activity of CBD in a mouse model of breast cancer was not reversed in the presence of a CB<sub>2</sub> receptor antagonist (Murase et al. 2014).

### **CBD-Dependent Release of Calcium from Intracellular Stores**

The initial events leading to CBD-dependent production of ROS in cancer cells is still not well understood. In hippocampal cultures, CBD induces a mitochondrial-dependent release of calcium. Under physiological conditions, CBD caused a subtle rise in calcium, but under high-excitability conditions CBD prevented calcium oscillations leading to neuroprotection (Ryan et al. 2009). In oligodendrocytes, however, CBD produced a concentration-dependent increase in calcium leading to alterations in mitochondrial membrane potential, production of ROS, and ultimately cytotoxicity Mato et al. (2010). In these cultures, the activity of CBD was not related to the activation of CB<sub>1</sub>, CB<sub>2</sub>, or TRPV1. Ligresti et al. also demonstrated that the ability of CBD to inhibit breast cancer cell viability through generation of ROS was calcium-dependent (Ligresti et al. 2006). Recently, it was demonstrated that CBD induced cell death in immortalized BV-2 microglial cells in part through inhibition of voltage-dependent anion channel 1 located in the mitochondrial outer membrane (Rimmerman et al. 2013). The CBD-dependent inhibition of this channel led to a biphasic increase in intracellular calcium levels leading to changes in mitochondrial function and morphology, and production of ROS. Taken together, these studies suggest that CBD interacts with unique mitochondrial sites leading to modulation of calcium homeostasis and ROS.

ROS can exert different effects according to the basal metabolic rate of the cell, and the high basal metabolic rate of cancer cells makes them more susceptible to redox-directed therapeutics in comparison to non-transformed cells (Laurent et al. 2005). The ability of CBD to more selectively reduce the viability/proliferation of cancer cells in comparison to non-transformed cells may be related to differences in metabolic rate, particularly considering that the origin of CBD-dependent production of ROS appears to stem primarily from the mitochondria. Redox-directed therapeutics have been developed to act as direct inhibitors of cancer and to sensitize

tumors to first-line agents; however, they are associated with significant toxicity (Wondrak 2009). Therefore, the discovery of natural non-toxic plant-based molecules that selectively up-regulate ROS in tumor cells would be beneficial.

### **A Diverse Range of Cannabinoids can Induce ER Stress and the Production of ROS**

Separate groups performed an unbiased screen of multiple plant and synthetic cannabinoids, and determined that CBD was consistently more potent at reducing cell viability/proliferation in comparison to classical CB<sub>1</sub> and CB<sub>2</sub> receptor agonists, including THC. While this holds true in culture, only two direct comparison of the antitumor activity of a classical CB<sub>1</sub> and CB<sub>2</sub> receptor agonist (THC) and CBD have been carried out *in vivo*. In tumors derived from subcutaneous implanted human GBM, THC but not CBD could produce moderate inhibition of tumor progression. However, in this study, it was demonstrated that the addition of CBD to THC enhanced its effects (Torres et al. 2011) thereby allowing a lower dose of THC to be used to produce equivalent antitumor activity. This study was in agreement with studies in culture (Marcu et al. 2010) demonstrating that CBD enhanced the inhibitory effects of THC on human GBM cell proliferation and survival. The ability of CBD to enhance the activity of THC was associated with the production of ROS leading to inhibition of pERK and activation of multiple caspases. In a more recent study, it was reported in a mouse model of breast cancer metastasis that CBD was more potent than THC at inhibiting the formation of lung metastatic foci (McAllister et al. 2007; Murase et al. 2014).

Another study in culture by Shrivastava et al. showed that targeting the human breast cancer cell line, MDA-MB231, with CBD led to endoplasmic reticulum stress, inhibition of the AKT/mTOR pathway, and up-regulation of autophagy-mediated cell death (Shrivastava et al. 2011). As discussed earlier, the targeting of these key pathways is also linked to the antitumor activity of CB<sub>1</sub> and CB<sub>2</sub> receptor agonists such as THC (Carracedo et al. 2006b; Salazar et al. 2009; Guindon and Hohmann 2011). Shrivastava et al. provided evidence that the effects of CBD were not the result of interactions with CB<sub>1</sub> and CB<sub>2</sub> receptors (Shrivastava et al. 2011). An intriguing recent study demonstrated that structurally diverse cannabinoids, including a CB<sub>1</sub> selective agonist, a CB<sub>1</sub> selective antagonist, and an endogenous CB<sub>1</sub> and CB<sub>2</sub> mixed agonist could all stimulate the generation ROS and production of autophagy in pancreatic tumor cells (Donadelli et al. 2011). This group went on to further demonstrate that CB<sub>1</sub>-selective and CB<sub>2</sub>-selective receptor agonists induced autophagic cell death in part through the initial induction of the ROS sensor AMP-activated protein kinase (AMPK) (Dando et al. 2013). More recently, CBD has been shown to enhance the ability of THC to inhibit tumor progression in mice bearing BRAF wildtype

melanoma xenografts through activation of autophagy-mediated cell death (Armstrong et al. 2015).

Of interest is an investigation by Sarker and Maruyama, where this group demonstrated that the endocannabinoid anandamide induced cell death in multiple cancer cell lines (Sarker and Maruyama 2003). In this study, it was demonstrated that formation of lipid rafts, leading to production of ROS, where part of the proposed mechanisms for the observed effects. Taken together, these data suggest that a diverse range of cannabinoids can induce ER stress and ROS generation, regardless of whether they activate or inhibit cannabinoid receptors, or in the case of CBD, do not efficiently target either CB<sub>1</sub> or CB<sub>2</sub> receptors. An important caveat in these studies is that modulation of autophagy and other proposed mechanisms were not confirmed *in vivo*. This is important since in GBM cells, while both THC and CBD were effective at reducing cell viability/proliferation in culture, only THC was effective at directly inducing autophagy *in vivo* (Torres et al. 2011). CBD however was able to enhance the ability of THC to induce autophagy, similar to what was reported in a mouse model of melanoma (Armstrong et al. 2015). In another recent study, where multiple GSCs were treated with CBD and then analyzed using Affymetrix microarrays, a robust up-regulation of TRIB3 was observed in all lines (Singer et al. 2015). In addition, in GSC-derived intracranial tumors treated with CBD, a marked down-regulation of pAKT activity was observed. Upregulation of TRIB3 and inhibition of pAKT are hallmarks of autophagy-mediated cell death (Cardaci et al. 2012; Sui et al. 2013). It has been shown that CBD is less potent than THC at inducing autophagy in human breast cancer cells (Murase et al. 2014). The concentration used in culture and doses used *in vivo* in the Torres et al. study were significantly lower than those used in the studies where up-regulation of autophagy was observed. This may explain the discrepancy between studies.

### **Inhibition of Invasion and Metastasis**

An exciting recent area of investigation for the therapeutic application of CBD resides in its ability to inhibit invasion and metastasis (Ligresti et al. 2006; McAllister et al. 2007; McAllister et al. 2010; Ramer et al. 2010a). While several cancer therapeutics on the market have been designed to target tumor cell survival, none have been specifically designed to inhibit metastasis. Migration is an important step in the process of metastasis. Vaccani et al. first reported that CBD could inhibit glioma cell migration (Vaccani et al. 2005). This effect could not be blocked by a CB<sub>1</sub> or CB<sub>2</sub> receptor antagonist or by pertussis toxin, an inhibitor of G<sub>i</sub> subunits of G-proteins. This however does not rule out the possibility that the effects of CBD on cell migration are produced through GPCR receptors signaling utilizing pertussis toxin insensitive G proteins such as G<sub>q</sub> or G<sub>12/13</sub> (Baldwin 1994).

Local invasion of cancer cells followed by invasion to secondary sites is one of the major hallmarks of metastasis. Therefore, in addition to inhibit of cancer cell migration, several groups have demonstrated that CBD could inhibit the invasion and metastasis of aggressive cancer cells (Ligresti et al. 2006; McAllister et al. 2007; Ramer et al. 2010a; McAllister et al. 2011; Ramer et al. 2011; Ramer et al. 2012; Soroceanu et al. 2013; Murase et al. 2014). Particularly, CBD turned off the expression of an important pro-metastatic gene, Id1, in breast and brain cancer cells in culture and in animal models (McAllister et al. 2007; Soroceanu et al. 2013; Murase et al. 2014). Id1 has been shown to play a key role in mediating breast cancer progression and metastasis to the lung (Fong et al. 2003; Minn et al. 2005; Gupta et al. 2007; Swarbrick et al. 2008). These data therefore suggested that the anti-invasive and anti-metastatic activity of CBD was primarily due to down-regulation of Id1 gene expression. Indeed, ectopic expression of Id1 in breast cancer cells reversed the anti-invasive and anti-metastatic activity of CBD (McAllister et al. 2007; Murase et al. 2014). Overall, these data suggest that Id1 represents a potential biomarker for predicting whether CBD would be effective at inhibiting metastatic progression. Additional mechanisms *in vivo* that have been implicated in the anti-metastatic activities of CBD include the up-regulation of intercellular adhesion molecule-1 (ICAM-1) and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in lung cancer (Ramer et al. 2012). Besides CBD, other cannabinoids such as JWH-015, Win55,212-2, or a non-psychotropic CB<sub>2</sub> receptor-selective agonist, JWH-133, significantly inhibited breast and lung cancer cell progression and metastasis (Qamri et al. 2009; Caffarel et al. 2010; Nasser et al. 2011; Preet et al. 2011).

A recent study demonstrated that CBD inhibits breast cancer primary tumor growth and metastasis through direct inhibition of EGF/EGFR signaling and the tumor microenvironment (Elbaz et al. 2015). CBD inhibited the activation of NF- $\kappa$ B, EGFR, ERK, AKT as well as matrix metalloproteinase 2 and 9 in human breast cancer cells. Importantly, many of the major findings were confirmed in syngeneic and genetic mouse models of breast cancer. Additionally, CBD inhibited the recruitment of tumor-associated macrophages (TAM). In line with these findings, CBD inhibited the secretion of cytokines from the breast cancer cells that are known to attract TAM (Elbaz et al. 2015).

### **Suppression of Angiogenesis**

Using human umbilical vein endothelial cells (HUVEC) in culture as a model, it was reported that CBD inhibited multiple processes involved in angiogenesis. Furthermore, this group significantly reduced angiogenesis *in vivo* in Matrigel sponges. Key down-stream targets inhibited by CBD in HUVEC cells included MMP-2 and -9, TIMP1, plasminogen

activator uPA, chemokines CXCL16 and IL-8, and growth factors endothelin-1 and platelet derived growth factor-AA (Solinas et al. 2012). Moreover, CBD treatment led to a decrease in CD31 (vascularization marker) staining in tumor stroma in a mouse xenograft model where tumors were derived from subcutaneously implanted human lung cancer cells (Ramer et al. 2013).

### **Inhibition of Cancer Stem Cell Self-Renewal**

Cancer stem cells are critical contributors to GBM therapeutic resistance and recurrence. It was demonstrated that CBD induced inhibition of patient-derived GSC self-renewal, and this effect was mediated by downregulation of expression levels of critical stem cell maintenance and growth regulators, such as Id1 and Sox2 (Soroceanu et al. 2013). More recently, it was shown that CBD inhibited self-renewal of GSCs in a ROS-dependent manner, by inhibiting phospho-STAT3 signaling as well as phospho-p38 MAP kinase pathway, both of which are key regulators of cancer stem cells (Singer et al. 2015). Furthermore, the study demonstrated that GSCs treated with CBD underwent a proneural to mesenchymal transition exhibiting downregulation of proneural markers such as Olig2, Sox2 and upregulation of mesenchymal markers, such as CD44 (Singer et al. 2015). A similar proneural to mesenchymal transition has been observed when GSCs were treated with radiation (Mao et al. 2013). In addition, the mesenchymal cells were shown to be markedly resistant to the effects of radiation. The CBD-dependent proneural to mesenchymal transition was reversed by anti-oxidant treatment, suggesting that ROS modulators may be used to prevent acquisition of a therapeutic resistant phenotype. Importantly, this study evaluated the efficacy of combining CBD with other small molecules that modulate system Xc and intracellular ROS, and showed a synergistic increase producing cell death when combining CBD and system Xc inhibitors (e.g., Erastin, Piperazine-erastin). System Xc has been shown to promote therapeutic resistance in several other cancers (Timmerman et al. 2013; Yoshikawa et al. 2013), therefore combining CBD with system Xc inhibitors may be efficacious in treating other malignancies in addition to glioblastoma.

### **Cannabinoids in Combination with First-Line Therapies**

As reviewed above, treatment of cancer cells with cannabinoids leads to production of ROS, inhibition of Id1 gene expression and upregulation of autophagy-mediated cell death. Drugs that stimulate ROS have been shown to sensitize

tumors to first-line agents (Wondrak 2009). Moreover, using genetic approaches to down-regulate Id1 expression has re-sensitized aggressive cancer cells to treatments with first-line therapies (Hu et al. 2009; Ponz-Sarvise et al. 2011). In breast cancer cells, where CBD is effective at downregulating Id1 expression, CBD enhanced the activity of the first-line agent, paclitaxel (Ward et al. 2014). Autophagy-mediated cell death mechanisms also contribute to efficacy of first-line therapies (Sui et al. 2013), and a primary mechanism for explaining the ability of a combination of THC and CBD to enhance the antitumor activity of temozolomide has indeed been upregulation of autophagy-mediated cell death (Torres et al. 2011). CBD and CBN have been shown to selectively decrease multidrug transporter expression leading to intracellular substrate accumulation and enhanced sensitivity of the cells to the cytotoxic actions of first-line therapies (Holland et al. 2006; Zhu et al. 2006; Holland et al. 2007). Two recent studies have investigated the ability of cannabinoids to enhance the effects of radiation in models of cancer. Emery et al. investigated the effects of THC and CBD to modulate the growth inhibitory effects of radiation in breast cancer cell lines in culture. Both cannabinoids did not alter the anti-proliferative effects of radiation (Emery et al. 2014). However, recent studies have evaluated the efficacy of CBD, THC or combinations thereof to enhance the anti-tumor effect of radiation using an immunocompetent orthotopic murine glioma model. Results showed that a combination of CBD and THC primed glioma cells to respond better to radiation suggesting a possible clinical benefit (Scott et al. 2014).

Another recent study investigated the ability of a variety of plant-derived cannabinoids to inhibit human prostate cancer (De Petrocellis et al. 2013). Of the cannabinoids tested, CBD was one of the most potent overall at inhibiting cell viability/proliferation. Xenograft tumors models utilizing human prostate cancer lines were then treated with a combination of CBD and the first-line agents taxotere and bicalutamide. A unique aspect of this study is that the mice were administered CBD orally, whereas a majority of cannabinoid antitumor investigations use systemic administration. As might be expected, there was heterogeneity in the response to treatment. CBD alone inhibited tumor progression in certain models but not in others, and enhanced the activity of first-line agents in two of the models but inhibited the efficacy of a first-line agent in one of the *in vivo* models.

Cannabinoids undergo significant first-pass metabolism after oral administration and this has been implicated in production of metabolites that reduce therapeutic activity (Perez-Reyes et al. 1973; Ohlsson et al. 1980). It would be of interest to determine whether the route of administration for delivery of cannabinoids is critical to antitumor activity and the enhancement of the effects of first-line therapies. There is no published research on the pharmacokinetics of cannabinoids

in relation to antitumor activity or sensitizing tumors to first-line agents. The antimetastatic activity of CBD during chronic systemic administration is observed in the range of 1–5 mg/kg (Ramer et al. 2010b; Murase et al. 2014). 15–25 mg/kg of CBD administered systemically and 10 mg/kg of CBD administered orally was needed to inhibit tumor progression in mouse xenograft models that more closely resemble primary tumor growth (Massi et al. 2004; Soroceanu et al. 2013; De Petrocellis et al. 2013). 3.7 mg/kg of CBD+3.7 mg/kg of THC delivered systemically and 100 mg/kg of CBD delivered orally were needed to sensitize tumors to first-line agents in mouse xenograft models that again more closely resemble primary tumor growth (Torres et al. 2011; De Petrocellis et al. 2013). Whether lower doses of CBD alone delivered orally would sensitize tumors to first-line agents has not been determined.

The significant psychotropic effects of THC would limit the use of high doses in humans. CBD however does not produce the psychotropic effects and has a low toxicity profile, therefore, using moderate to high doses of the drug is potentially feasible. The moderate effects of cannabinoids alone in mouse xenograft models that more closely resemble primary tumor growth suggest they may not be viable as a single drug therapy. This is not the case in models of metastasis, where the effects of cannabinoids appear to be more robust, particularly cannabinoid analogs (Murase et al. 2014). Cannabinoids however also sensitize, and in some cases resensitize, tumors to first-line agents (Torres et al. 2011). A cannabinoid drug treatment with a low toxicity profile that together produces direct antitumor activity and sensitizes tumors to existing first-line agents is an attractive therapeutic modality. This may explain why multiple groups are now in the process of initiating clinical trials to directly target aggressive cancer using cannabinoid-based therapeutics.

Since, the heterogeneous nature of tumors results in varying response to therapeutic treatments, a goal in treating cancer patients with cannabinoids would be to develop “signatures” that can predict which patient tumors will respond best to cannabinoids alone or in combination with first-line therapies. One of the first goals in this pursuit would be to determine the major pathways underlying treatment efficacy with non-psychoactive cannabinoids, in particular CBD.

## Summary

Over the past decade researchers have refocused their efforts on the therapeutic potential of non-psychoactive cannabinoids in CS, in particular CBD. As presented in this review, the preclinical data strongly support the notion that non-psychoactive plant-derived CBs can act as direct inhibitors of tumor progression as well as enhance the activity of first-line therapies. While many anecdotal reports by cancer patients using various formulations of CS suggest significant

efficacy, the lack of pure pharmacologically active compounds and legal restrictions surrounding schedule I drugs have delayed the clinical research that will ultimately determine whether cannabinoids are effective in the treatment of cancer beyond their proven palliative effects. It is promising to note that pharmaceutical companies have initiated clinical programs that include GMP-grade cannabinoids for targeting glioblastoma. Elucidation of the molecular pathways mediating non-psychoactive cannabinoid antitumor effects will be particularly important as the drugs move toward the clinic. As discussed earlier, certain tumors appear to be responsive to treatments while others are not. Currently, no markers have been discovered that can help oncologists identify which patients might benefit most from treatment with cannabinoids. Additional basic research will help lead to the development of cannabinoid-based therapies for the treatment of aggressive cancers and will also bring us closer to understanding the novel CB<sub>1</sub>- and CB<sub>2</sub>-independent component of the cannabinoid system that controls cancer progression.

**Conflict of Interest** The authors declare that they have no conflict of interest.

## References

- Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister LE (1981) Interactions of delta 1-tetrahydrocannabinol with cannabidiol and cannabidiol following oral administration in man. Assay of cannabidiol and cannabidiol by mass fragmentography. *Experientia* 37:1090–1092
- Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, Pestell RG (1995) Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. *J Biol Chem* 270:23589–23597
- Alozie SO, Martin BR, Harris LS, Dewey WL (1980) 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain. *Pharmacol Biochem Behav* 12:217–218
- Armstrong JL, Hill DS, McKee CS, Hernandez-Tiedra S, Lorente M, Lopez-Valero I, Eleni Anagnostou M, Babatunde F, Corazzari M, Redfern CP, Velasco G and Lovat PE (2015) Exploiting Cannabinoid-Induced Cytotoxic Autophagy to Drive Melanoma Cell Death. *J Invest Dermatol*
- Baldwin JM (1994) Structure and function of receptors coupled to G proteins. *Curr Opin Cell Biol* 6
- Bifulco M, Di Marzo V (2002) Targeting the endocannabinoid system in cancer therapy: a call for further research. *Nat Med* 8:547–550
- Bornheim LM, Grillo MP (1998) Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. *Chem Res Toxicol* 11:1209–1216
- Brady KT, Balster RL (1980) The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys. *Psychopharmacology* 72:21–26
- Caffarel MM, Andradas C, Mira E, Perez-Gomez E, Cerutti C, Moreno-Bueno G, Flores JM, Garcia-Real I, Palacios J, Manes S, Guzman

- M, Sanchez C (2010) Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. *Mol Cancer* 9:196
- Cardaci S, Filomeni G, Ciriolo MR (2012) Redox implications of AMPK-mediated signal transduction beyond energetic clues. *J Cell Sci* 125:2115–2125
- Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, Velasco G, Iovanna JL (2006a) Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. *Cancer Res* 66:6748–6755
- Carracedo A, Lorente M, Egia A, Blazquez C, Garcia S, Giroux V, Malicet C, Villuendas R, Gironella M, Gonzalez-Feria L, Piris MA, Iovanna JL, Guzman M, Velasco G (2006b) The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. *Cancer Cell* 9:301–312
- Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976) Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. *Clin Pharmacol Ther* 19:300–309
- Dando I, Donadelli M, Costanzo C, Dalla Pozza E, D'Alessandro A, Zolla L, Palmieri M (2013) Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. *Cell Death Dis* 4:e664
- Davis WM, Hatoum NS (1983) Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. *Gen Pharmacol* 14:247–252
- De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V (2013) Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. *Br J Pharmacol* 168:79–102
- Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla Pozza E, Scupoli MT, Scarpa A, Zappavigna S, Marra M, Abbruzzese A, Bifulco M, Caraglia M, Palmieri M (2011) Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. *Cell Death Dis* 2:e152
- Ederly H, Grunfeld Y, Ben-Zvi Z, Mechoulam R (1971) Structural requirements for cannabinoid activity. *Ann NY Acad Sci* 191:40–53
- Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, Oghumu S, Satoskar AR, Shilo K, Carson WE, 3rd and Ganju RK (2015) Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer. *Mol Oncol*
- Emery SM, Alotaibi MR, Tao Q, Selley DE, Lichtman AH, Gewirtz DA (2014) Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells. *J Pharmacol Exp Ther* 348:293–302
- Flygare J, Sander B (2008) The endocannabinoid system in cancer-potential therapeutic target? *Semin Cancer Biol* 18:176–189
- Fong S, Itahana Y, Sumida T, Singh J, Coppe JP, Liu Y, Richards PC, Bennington JL, Lee NM, Debs RJ, Desprez PY (2003) Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. *Proc Natl Acad Sci U S A* 100:13543–13548
- Freimuth N, Ramer R, Hinz B (2010) Antitumorogenic effects of cannabinoids beyond apoptosis. *J Pharmacol Exp Ther* 332:336–344
- Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. *Nat Med* 6:313–319
- Guimaraes FS, de Aguiar JC, Mechoulam R, Breuer A (1994) Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. *Gen Pharmacol* 25:161–164
- Guindon J, Hohmann AG (2011) The endocannabinoid system and cancer: therapeutic implication. *Br J Pharmacol* 163:1447–1463
- Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, Gerald WL, Brogi E, Benezra R, Massague J (2007) ID genes mediate tumor reinitiation during breast cancer lung metastasis. *Proc Natl Acad Sci U S A* 104:19506–19511
- Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)-Delta9-tetrahydrocannabinol are neuroprotective antioxidants. *Proc Natl Acad Sci U S A* 95:8268–8273
- Hiltunen AJ, Jarbe TU, Wangdahl K (1988) Cannabinol and cannabidiol in combination: temperature, open-field activity, and vocalization. *Pharmacol Biochem Behav* 30:675–678
- Hiltunen AJ, Jarbe TU, Kamkar MR, Archer T (1989) Behaviour in rats maintained by low differential reinforcement rate: effects of delta 1-tetrahydrocannabinol, cannabiniol and cannabidiol, alone and in combination. *Neuropharmacology* 28:183–189
- Holland ML, Panetta JA, Hoskins JM, Bebowy M, Roufogalis BD, Allen JD, Arnold JC (2006) The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. *Biochem Pharmacol* 71:1146–1154
- Holland ML, Lau DT, Allen JD, Arnold JC (2007) The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. *Br J Pharmacol* 152:815–824
- Hollister LE, Gillespie H (1975) Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol. *Clin Pharmacol Ther* 18:80–83
- Howlett AC (1987) Cannabinoid inhibition of adenylate cyclase: relative activity of the constituents and metabolites of marijuana. *Neuropharmacology* 26:507–512
- Hu H, Han HY, Wang YL, Zhang XP, Chua CW, Wong YC, Wang XF, Ling MT, Xu KX (2009) The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells. *Oncol Rep* 21:1053–1059
- Huffman JW, Shu Y, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett DR, Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. *J Med Chem* 39:3875–3877
- Hunt CA, Jones RT, Herning RI, Bachman J (1981) Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. *J Pharmacokinetics Biopharm* 9:245–260
- Jacobsson SO, Rongard E, Stridh M, Tiger G, Fowler CJ (2000) Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. *Biochem Pharmacol* 60:1807–1813
- Jaeger W, Benet LZ, Bornheim LM (1996) Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. *Xenobiotica* 26:275–284
- Jarbe TU, Hiltunen AJ (1987) Cannabimimetic activity of cannabiniol in rats and pigeons. *Neuropharmacology* 26:219–228
- Karler R, Turkkanis SA (1979) Cannabis and epilepsy. In: Nahas GG, Paton WDM (eds) Marijuana: biological effects, analysis, metabolism, cellular responses, reproduction and brain. Pergamon Press, Oxford, pp 619–641
- Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nat Rev Immunol* 5:400–411
- Kogan NM, Rabinowitz R, Levi P, Gibson D, Sandor P, Schlesinger M, Mechoulam R (2004) Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. *J Med Chem* 47:3800–3806
- Kogan NM, Schlesinger M, Priel E, Rabinowitz R, Berenshtein E, Chevion M, Mechoulam R (2007) HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. *Mol Cancer Ther* 6:173–183
- Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A, Levy E, Goldwasser F, Panis Y, Soubrane O, Weill B, Batteux F (2005) Controlling tumor growth by modulating endogenous production of reactive oxygen species. *Cancer Res* 65:948–956
- Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, Laezza C, Portella G, Bifulco M, Di Marzo V (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J Pharmacol Exp Ther* 318:1375–1387
- Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreaskos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis

- constituent cannabidiol is an oral anti-arthritis therapeutic in murine collagen-induced arthritis. *Proc Natl Acad Sci U S A* 97:9561–9566
- Mao P, Joshi K, Li J, Kim SH, Li P, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, Wang M, Hu B, Cheng SY, Sobol RW, Nakano I (2013) Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. *Proc Natl Acad Sci U S A* 110:8644–8649
- Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J, Pakdel A, Allison J, Limbad C, Moore DH, Yount GL, Desprez PY, McAllister SD (2010) Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. *Mol Cancer Ther* 9:180–189
- Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. *J Pharmacol Exp Ther* 308:838–845
- Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D (2006) The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. *Cell Mol Life Sci* 63:2057–2066
- Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, Fezza F, Maccarrone M and Parolaro D (2008) 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. *J Neurochem* 104:1091–1100
- Massi P, Solinas M, Cinquina V, Parolaro D (2012) Cannabidiol as potential anticancer drug. *Br J Clin Pharmacol* 75:303–312
- Mato S, Victoria Sanchez-Gomez M, Matute C (2010) Cannabidiol induces intracellular calcium elevation and cytotoxicity in oligodendrocytes. *Glia* 58:1739–1747
- McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007) Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. *Mol Cancer Ther* 6:2921–2927
- McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C, Pakdel A, Lee J, Limbad C, Liu Y, Debs RJ, Moore DH, Desprez PY (2010) Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. *Breast Cancer Res Treat* 129:37–47
- McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M (2006) Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. *Mol Pharmacol* 70:897–908
- McPartland JM, Russo EB (2001) Cannabis and cannabis extract: greater than the sum of the parts? *J Cannabis Therapeut* 1:103–132
- Mechoulam R, Ben-Shabat S, Hanus S, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almong S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of a 2-mono-glyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* 50:83–90
- Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J (2005) Genes that mediate breast cancer metastasis to lung. *Nature* 436:518–524
- Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J, Elwakeel E, Dayal S, Martinez-Martinez E, Amere M, Gujjar R, Mahadevan A, Desprez PY, McAllister SD (2014) Targeting multiple cannabinoid antitumor pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. *Br J Pharmacol* 171:4464–4477
- Nasser MW, Qamri Z, Deol YS, Smith D, Shilo K, Zou X, Ganju RK (2011) Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. *PLoS One* 6:e23901
- Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980) Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. *Clin Pharmacol Ther* 28:409–416
- Perez-Reyes M, Timmons MC, Davis KH, Wall EM (1973) A comparison of the pharmacological activity in man of intravenously administered D9-tetrahydrocannabinol, cannabinol, and cannabidiol. *Experientia* 29:1368–1369
- Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. *Pharmacol Ther* 74:129–180
- Pertwee RG (2006) Cannabinoid pharmacology: the first 66 years. *Br J Pharmacol* 147(Suppl 1):S163–S171
- Piomelli D (2003) The molecular logic of endocannabinoid signalling. *Nat Rev Neurosci* 4:873–884
- Ponz-Sarvise M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, Pio R, Behrens C, Wistuba II, Garcia-Franco CE, Garcia-Foncillas J, Montuenga LM, Calvo A, Gil-Bazo I (2011) Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. *Clin Cancer Res* 17:4155–4166
- Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, Groopman JE, Ganju RK (2011) Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. *Cancer Prev Res (Phila)* 4:65–75
- Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK (2009) Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. *Mol Cancer Ther* 8:3117–3129
- Ramer R, Hinz B (2008) Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. *J Natl Cancer Inst* 100:59–69
- Ramer R, Merkord J, Rohde H, Hinz B (2010a) Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. *Biochem Pharmacol* 79:955–966
- Ramer R, Rohde A, Merkord J, Rohde H, Hinz B (2010b) Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. *Pharm Res* 27:2162–2174
- Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M, Borchert P, Schmuhl E, Linnebacher M, Hinz B (2011) Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. *FASEB J* 26:1535–1548
- Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Hinz B (2013) COX-2 and PPAR-gamma confer cannabidiol-induced apoptosis of human lung cancer cells. *Mol Cancer Ther* 12:69–82
- Rimmerman N, Ben-Hail D, Porat Z, Juknat A, Kozela E, Daniels MP, Connelly PS, Leishman E, Bradshaw HB, Shoshan-Barmatz V, Vogel Z (2013) Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. *Cell Death Dis* 4:e949
- Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B (2009) Cannabidiol targets mitochondria to regulate intracellular Ca<sup>2+</sup> levels. *J Neurosci* 29:2053–2063
- Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, Egia A, Vazquez P, Blazquez C, Torres S, Garcia S, Nowak J, Fimia GM, Piacentini M, Cecconi F, Pandolfi PP, Gonzalez-Feria L, Iovanna JL, Guzman M, Boya P, Velasco G (2009) Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. *J Clin Invest* 119:1359–1372
- Sarfraz S, Afaq F, Adhami VM, Malik A, Mukhtar H (2006) Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. *J Biol Chem* 281:39480–39491
- Sarfraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H (2008) Cannabinoids for cancer treatment: progress and promise. *Cancer Res* 68:339–342
- Sarker KP, Maruyama I (2003) Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. *Cell Mol Life Sci* 60:1200–1208

- Scott KA, Dalglish AG, Liu WM (2014) The combination of cannabidiol and Delta9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. *Mol Cancer Ther* 13:2955–2967
- Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A (2011) Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. *Mol Cancer Ther* 10:1161–1172
- Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, Soroceanu L (2015) Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. *Cell Death Dis* 6:e1601
- Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, Cinquina V, Valenti M, Vicentini LM, Noonan DM, Albini A, Parolaro D (2012) Cannabidiol inhibits angiogenesis by multiple mechanisms. *Br J Pharmacol* 167:1218–1231
- Soroceanu L, Murase R, Limbad C, Singer EL, Allison J, Adrados I, Kawamura R, Pakdel A, Fukuyo Y, Nguyen D, Khan S, Arauz R, Yount GL, Moore D, Desprez PY, McAllister SD (2013) Id-1 is a Key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. *Cancer Res* 73:1559–1569
- Srivastava MD, Srivastava BI, Brouhard B (1998) Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. *Immunopharmacology* 40:179–185
- Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonoylglycerol: a possible cannabinoid receptor ligand in the brain. *Biochem Biophys Res Commun* 215:89–97
- Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. *Cell Death Dis* 4:e838
- Swarbrick A, Roy E, Allen T, Bishop JM (2008) Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. *Proc Natl Acad Sci U S A* 105:5402–5407
- Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, Hu M, Chan DA, Ethier SP, van't Veer LJ, Polyak K, McCormick F, Gray JW (2013) Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. *Cancer Cell* 24:450–465
- Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E, Barcia J, Guzman M, Velasco G (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. *Mol Cancer Ther* 10:90–103
- Turkanis SA, Karler R (1975) Influence of anticonvulsant cannabinoids on posttetanic potentiation at isolated bullfrog ganglia. *Life Sci* 17:569–578
- Turner CE, Elsohly MA, Boeren EG (1980) Constituents of *Cannabis sativa* L. XVII. A review of the natural constituents. *J Nat Prod* 43:169–234
- Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D (2005) Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. *Br J Pharmacol* 144:1032–1036
- Velasco G, Galve-Roperh I, Sanchez C, Blazquez C, Guzman M (2004) Hypothesis: cannabinoid therapy for the treatment of gliomas? *Neuropharmacology* 47:315–323
- Velasco G, Sanchez C, Guzman M (2012) Towards the use of cannabinoids as antitumour agents. *Nat Rev Cancer* 12:436–444
- Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA (2014) Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. *Br J Pharmacol* 171:636–645
- Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. *Science* 296:678–682
- Wondrak GT (2009) Redox-directed cancer therapeutics: molecular mechanisms and opportunities. *Antioxid Redox Signal* 11:3013–3069
- Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O (2013) xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. *Cancer Res* 73:1855–1866
- Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, Gefroh HA, Devane CL (2006) Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. *J Pharmacol Exp Ther* 317:850–857
- Zuardi AW (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. *Rev Bras Psiquiatr* 30:271–280